To receive your instant certificate, you must "Sign In" or "Sign Up" in the top right corner.
ORIGINAL RELEASE: May 31, 2021
EXPIRATION: May 31, 2022
MAXIMUM CREDITS: 1.0 AMA PRA Category 1 Credit™
CLICK BELOW TO PROCEED TO PROGRAM
ACTIVITY DESCRIPTION AND PURPOSE
Age-related macular degeneration (AMD) is a leading cause of vision loss in Canada, preferentially affecting White patients aged ≥ 75 years. The prevalence of vision-threatening advanced AMD is also steadily increasing as the population ages. The standard of care for neovascular AMD (nAMD) is anti–vascular endothelial growth factor injections, but a growing body of real-world studies indicates that patients do not achieve comparable visual acuity outcomes to those in landmark clinical trials. In particular, patients in Canada are older and have poorer visual acuity at diagnosis, leading to poor long-term visual outcomes, compared with those in other developed countries. To address these unmet needs, accumulating evidence supports regular disease screening and monitoring using optical coherence tomography and individualized dosing. In rural areas, and considering the ongoing COVID-19 pandemic, frequent monitoring and image interpretation present challenges that may be overcome using artificial intelligence and newer technologies. In this educational activity, derived from a roundtable discussion, experts interpret the latest data and provide actionable insights to meet the needs of Canadians with nAMD or those at risk of development of nAMD in a previously unaffected eye. The desired outcomes of this activity are for retina specialists and other ophthalmologists to better evaluate recent research on the clinical relevance of fluid on optical coherence tomography and apply the evidence to assess current and emerging treatment strategies and therapies.
This continuing medical education activity is provided by MedEdicus LLC.
This continuing medical education activity is supported through an educational grant from Bayer Inc.
This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 241 CLICK HERE TO PROCEED TO PROGRAM